VINDA INTERNATIONAL HOLDINGS LIMITED

Income statement

Notes. FY2020 net profit (HK$1,874m) is derived from the disclosed FY2021 figure of HK$1,638m, described as a 12.6% decline, and is consistent with FY2020 EPS of 156.5 HK cents. The FY2023 growth rate is reported in HK$; organic growth was 6.9% (HKEX FY2023 results). The FY2021 constant-currency growth rate was 7.0%. Diluted EPS was not separately verified; Vinda's dilution was historically immaterial.

H1 2023 EBITDA was HK$818m, a margin of 8.1% (Phillip Securities summary of HKEX interim results). Pre-tax income: not separately verified in the materials reviewed.

Revenue CAGR, FY2020–FY2023: 6.6% in HK$ (derived: 19,999 / 16,512 over three years).

Half-year profile (shows inflection points)

Sources: HKEX interim results 2021, 2022 and 2023. H2 figures are derived as the full year less H1. Quarterly detail: Q1 2023 revenue was HK$4,969m (+15.5% at constant FX), with gross profit of HK$1,254m, operating profit of HK$65m and net profit of HK$40m. Q2 2023 revenue was HK$5,101m (HKEX Q1 2023 inside information announcement, 27 Apr 2023; Phillip Securities).

Commentary — trends, inflections and drivers.

FY2020 was the profitability peak: Net margin reached 11.3% and EBITDA margin 21.8%, as pulp prices troughed in 2019–2020 and COVID-19 boosted hygiene demand. Q1 2020 net profit rose 64.8% even as revenue fell 16.2% on supply shortages in Mainland China (The Standard).

FY2021 delivered record revenue but lower profit: Revenue grew 13.1% (7.0% at constant FX) on HK$ translation gains, e-commerce growth of 26% in H1 and premiumisation. However, pulp inflation began in H2 2021: the gross margin fell from 37.4% in H1 to 33.4% in H2, and operating profit fell 16.7%.

FY2022 marked the margin collapse: H2 2022 was the trough: a gross margin of 24.5%, operating profit of only HK$50m and net profit of HK$68m. Management attributed this to significantly higher input costs (pulp and energy), promotional pressure, and the HK$ translation impact of a weaker RMB. Pricing actions improved net selling prices but lagged costs (HKEX FY2022 results).

FY2023 brought a sequential recovery but a weak full year: Pulp prices fell from late 2022, but high-cost inventory depressed H1 2023 (gross margin 25.1%). The gross margin recovered to an estimated 27.4% in H2 2023. Management also cited inflationary pressure and intensified market competition. Organic revenue growth of 6.9%, with strong organic growth in Mainland China driven by product mix and volume, was largely erased in HK$ terms by RMB weakness.

• Overall, the business is volume-resilient but margin-volatile. Revenue rose every year from FY2020 to FY2023, while net profit fell 87% over the same period. This asymmetry is the central fact behind both the low pre-offer valuation and RGE's integration rationale: owning the pulp cost line neutralises the main source of volatility.

Balance sheet and leverage

Sources: HKEX FY2021–FY2023 annual reports. Net gearing is net debt (total debt including lease liabilities, less cash and restricted deposits) divided by total shareholders' equity, as defined by Vinda. Net debt and equity are approximations derived from rounded disclosed ratios (net debt = ND/EBITDA × EBITDA; equity = net debt ÷ net gearing). They are indicative only, with an error margin of several per cent. Net asset value per share was HK$9.41 at 30 June 2023, implying equity of roughly HK$11.3bn on about 1.2bn shares (Isola Castle offer announcement, via CNN Indonesia/Reuters). Net gearing peaked intra-year at 43.1% at 30 June 2023, versus 23.9% at 30 June 2022, reflecting seasonal working capital and dividend timing.

The FY2023 annual report (HKEX, 28 Mar 2024) contains these figures in its consolidated balance sheet and five-year financial summary.

Cash flow

Qualitatively: Vinda paid a progressive dividend through FY2021 (47 to 50 HK cents), cut it to 40 HK cents in FY2022, and paid a 10 HK-cent interim in FY2023. Implied cash dividends were roughly HK$0.5–0.6bn a year in FY2020–FY2022 (derived from DPS × about 1.2bn shares). No share buybacks were identified. Capex was directed at tissue capacity and technology, including four Valmet Hybrid tissue machines (Tissue World, 2022).

Ratios

ROE is derived as net profit divided by approximate derived year-end equity. FY2023 uses equity of about HK$11.3bn, based on NAV per share of HK$9.41 at June 2023, and is therefore approximate.

Ratio commentary. Leverage stayed moderate through the downturn (net gearing fell every year as working capital was managed and dividends were trimmed). Returns, however, collapsed: ROE fell from roughly 16% to roughly 2%. This combination of a solvent balance sheet with depressed earnings is a classic precondition for a take-private by a strategic buyer with a lower cost of capital or a synergistic cost base.

Management guidance. None. Vinda provides no public guidance as a private company. RGE's stated aspiration is for Vinda to be the No.1 tissue and personal care company in Asia by 2030.

Consensus growth expectations. None (no analyst coverage). Peer read-across: Hengan expects stable full-year 2026 revenue with margin support from premiumisation and lower pulp costs (Quartr, H1 2026).

Bull case

1. Integration-led margin recovery. With pulp now in-group and 2026 pulp costs lower (peer gross margins up 3 points), Vinda's gross margin could revert toward the 32–35% achieved in FY2021–H1 2022. That would lift EBITDA well above the FY2022 level of HK$2.1bn.

2. Capacity and share gains. The six-machine Hubei expansion (June 2026) plus group Rizhao capacity (+150,000 tpy) would allow Vinda to press its claimed national sales leadership while weaker non-integrated mills struggle with overcapacity.

3. Structural demand growth in Asia. Emerging markets' rising share of global tissue value (45% in 2025) and ageing-driven incontinence demand support a mid-single-digit organic growth algorithm, in line with Vinda's 6.9% organic growth in FY2023.

Bear case

1. Licence erosion. The Essity licences are now arm's-length and Essity is reviewing or preparing to sell Consumer Tissue. Loss or repricing of Tempo, TENA, Tork, Libresse or Libero rights would hollow out the premium and personal care portfolio.

2. Price war absorbs cost savings. Chinese tissue overcapacity and promotional intensity (Hengan revenue -6.1% in H1 2026) may pass pulp savings to consumers, as happened in FY2023 when organic growth did not translate into profit.

3. Leverage and opacity. The US$3.4–3.6bn take-private was debt-financed at group level. With no public reporting, Vinda's cash flows may be prioritised for parent debt service over brand investment, and stakeholders cannot monitor this.

Key catalysts and monitorables (next 12 months)

Concluding analyst verdict. Vinda is best understood today not as an investable security but as a strategic asset inside a pulp conglomerate. As a listed company, its record from FY2020 to FY2023 told a stark story: revenue compounded at 6.6% while net profit fell 87%, from HK$1,874m to HK$253m, as pulp inflation and Chinese promotional competition crushed a business that had no control over its principal input. That disconnect, together with a solvent balance sheet (net gearing of 26.1%) and a depressed ROE of roughly 2%, set the stage for RGE's HK$23.50-per-share take-private. The price was rich on trough earnings (about 112x FY2023 EPS) but reasonable on normalised earnings (about 17x FY2021), and Sodali's 90%-plus acceptance in two weeks suggests minority shareholders saw it that way too. Strategically, the deal is coherent. RGE gains a branded, scale distribution outlet with a claimed decade of national tissue sales leadership. Vinda gains captive fibre, deep-pocketed capex support (visible in the June 2026 Hubei machine order) and insulation from the pulp cycle that destroyed its margins. In 2026, a benign pulp environment and peer margin expansion suggest Vinda's profitability has likely recovered materially since FY2023, but this cannot be verified because figures are not publicly disclosed. The principal medium-term risks are the Essity licences, now arm's-length and complicated by Essity's own Consumer Tissue review, and the chronic overcapacity and price competition in Chinese tissue, which could transfer integration savings to consumers rather than margins. Our assessment: operationally stronger than at any point since 2021, strategically well positioned within RGE, but opaque. For counterparties, the key diligence points are the licence terms, group-level leverage, and quality-control execution on the expanded capacity base. A future re-listing or brand-level transaction cannot be ruled out but has not been signalled.